The two main attributes of cancer are: 1) uncontrolled growth of abnormal cells in the human body, and 2) the ability of these abnormal cells to migrate from the original site and spread to other parts of the body.

The reason cancer is a formidable opponent for our body’s immune system is because our immune system is designed to protect us from foreign antigens, such as viruses and bacteria. However, in some cases cancer cells are not specifically detected and targeted by the human immune system because cancer cells are the patient’s own cells, and/or cancer cells trigger mechanisms that prevent detection. As a result of these two circumstances which frequently work in concert, cancer cells often go undetected and replicate until they become harmful to the body. That is why advances in immunotherapy, which activate the body’s immune system to detect and treat cancer, are so encouraging.

At Benovus Bio, we are focused on developing products that harness both the T cell (Peptides) and B cell (Monoclonal Antibodies) response as a means to more effectively treat cancer patients. Both immunotherapeutic approaches specifically target cancer cells, as well as both immunotherapeutic approaches do not have the significant side effects that often accompany more traditional cancer treatment therapies.